DelveInsight’s, “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the MALT Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the MALT Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ MALT Lymphoma Pipeline Outlook
Key Takeaways from the MALT Lymphoma Pipeline Report
- In May 2025, Incyte Corporation announced a study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.
- In May 2025, Regeneron Pharmaceuticals announced a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called “relapsed”), or did not respond to treatment (called “refractory”). FL and MZL are subtypes of Non-Hodgkin ‘s lymphoma (NHL).
- In May 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
- DelveInsight’s MALT Lymphoma Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for MALT Lymphoma treatment.
- Promising MALT Lymphoma Companies such as MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
- The leading MALT Lymphoma Pipeline Therapies such as Fludarabine, Rituximab, ibrutinib, milatuzumab, veltuzumab, Cytoxan and others.
Stay ahead with the most recent pipeline outlook for MALT Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ MALT Lymphoma Treatment Drugs
MALT Lymphoma Emerging Drugs Profile
- Tafasitamab: Incyte
Tafasitamab (MOR208) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. Tafasitamab (MOR208, formerly Xmab®5574) is an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). Tafasitamab (MOR208) binds to CD19. This antigen is broadly and homogeneously expressed across different B cell malignancies including diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CD19 is able to enhance B cell receptor (BCR) signaling, which is important for B cell survival. Therefore, CD19 is considered a potential therapeutic target for drugs aimed at treating B cell-related lymphomas and leukemias. Currently the product is in Phase III stage of development for the treatment of Malt Lymphoma.
The MALT Lymphoma Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of MALT Lymphoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for MALT Lymphoma Treatment.
- MALT Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- MALT Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the MALT Lymphoma market
Explore groundbreaking therapies and clinical trials in the MALT Lymphoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New MALT Lymphoma Drugs
MALT Lymphoma Companies
MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
Malt Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Small Molecule
- Gene Therapy
- Peptide
- Immunotherapy
- Cell Therapy
MALT Lymphoma Products have been categorized under various Molecule types such as
- Intravenous
- Intradermal
- Oral
- Subcutaneous
- Intramuscular
Unveil the future of MALT Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ MALT Lymphoma Market Drivers and Barriers
Scope of the MALT Lymphoma Pipeline Report
- Coverage- Global
- MALT Lymphoma Companies- MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
- MALT Lymphoma Pipeline Therapies- Fludarabine, Rituximab, ibrutinib, milatuzumab, veltuzumab, Cytoxan and others.
- MALT Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- MALT Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on MALT Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ MALT Lymphoma Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Malt Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Malt Lymphoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tafasitamab: Incyte
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Mosunetuzumab: Genentech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- BGB-10188: BeiGene
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- PSB202: Sound Biologics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Malt Lymphoma Key Companies
- Malt Lymphoma Key Products
- Malt Lymphoma – Unmet Needs
- Malt Lymphoma – Market Drivers and Barriers
- Malt Lymphoma – Future Perspectives and Conclusion
- Malt Lymphoma Analyst Views
- Malt Lymphoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/malt-lymphoma-pipeline-insight